Navigation Links
Possible new therapy for the treatment of a common blood cancer
Date:9/5/2012

Research from Karolinska Institutet in Sweden shows that sorafenib, a drug used for advanced cancer of the kidneys and liver, could also be effective against multiple myeloma. The disease is one of the more common forms of blood cancer and is generally incurable.

"Recently developed drugs, like bortezomib, have increased the survival rate for people with this serious and complex disease," says study leader Theocharis Panaretakis, docent of experimental oncology. "Having said this, the heterogeneity of the disease progression, the treatment response and the development of resistance to administered drugs which leads to the relapse of nearly all patients, has compelled us to find new and better treatments."

Myeloma is only found in adults; it is uncommon before the age of 40, and most patients are over 60 years when diagnosed. The disease can lie dormant in the body for many years, but only becomes life-threatening and requires treatment once the patient has begun to exhibit symptoms. The myeloma cells are mainly located in the bone marrow, and since this is where blood cells are produced, their presence seriously disrupts regular blood production. Malignant cancer cells or tumours can also accumulate outside the bone marrow, hence the term "multiple".

A common effect of multiple myeloma is osteoporosis, and as a consequence patients develop intense back pain as their vertebrae become compressed as well as bone fractures. Other symptoms are anaemia, fatigue, renal failure and, often, a greater susceptibility to infection.

The current study, which is published in the scientific journal Cancer Research, was conducted on cell samples from humans and mice (cell lines). Almost all myleoma patients, seen at Karolinska University Hospital, were previously untreated.

The researchers show how sorafenib induces cell death in human myeloma cell lines in a laboratory environment by preventing a certain kind of protein-level activity, an effect that also was achieved when the myeloma cells had developed a resistance to bortezomib. They also tested sorafenib in live mice and found that the drug either prevented or delayed the course of the disease. All in all, the researchers maintain that their results support the use of sorafenib in combination with other drugs in the treatment of multiple myeloma.

Research groups from Uppsala University and Belgium were also involved in the study. The project was financed by the Swedish Cancer Society, the Swedish Research Council, the Cancer Society in Stockholm and the ke Wiberg Foundation.


'/>"/>
Contact: Katarina Sternudd, Press Officer
katarina.sternudd@ki.se
46-852-483-895
Karolinska Institutet
Source:Eurekalert

Related medicine news :

1. Possible new cancer treatment identified
2. Study identifies possible protective blood factors against Type 2 diabetes
3. First study investigating possible link between sunscreen ingredient and endometriosis
4. Scientists identify possible drug target for acute pancreatitis
5. High-contrast, high-resolution CT scans now possible at reduced dose
6. US Drug Watchdog Dramatically Increases Their Efforts To Get All Recalled DePuy ASR Hip Implant Recipients Identified To The Best Possible Attorneys Before Time Runs Out
7. The US Drug Watchdog Now Urges Plaintiffs Law Firms Worldwide To Contact Them About A Possible International Effort To Help Victims Of Defective Drugs Or Medical Devices
8. Higher energies for laser-accelerated particles possible
9. Loss of protein SPDEF allows prostate cancer cells to gain foothold at possible sites of metastasis
10. Mutation in gene IDH a possible target for AML treatment
11. Mild HIV type slows development of AIDS and makes new preventive treatments possible
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... Aimed at nurses and employees in the health care world, this installment ... nursing and health care industry. It also provides insight to the developing trends and ... As the nursing industry is coming out of one of the biggest recessions in ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... ... May 26, 2016 , ... There are many ways to cook a ... (NHDSC) suggests that Americans prefer their dogs straight off the grill. Of the 90 ... their favorite way to cook a hot dog, far outpacing other cooking methods such ...
(Date:5/26/2016)... ... 26, 2016 , ... Cabot Corporation, Pfizer, and 3M are ... court documents and SEC filings. A jury has returned a verdict of ... Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded $22.8 million ...
(Date:5/26/2016)... ... 26, 2016 , ... Georgia State University College of Law ... , Answering to the increasing demand for curricular specializations, the Certificate in Intellectual ... and land use law. ,  , “The demand for lawyers with specific knowledge ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... -- According to the 2016 report, a ... blood pressure monitoring system market growth. With aging, the ... respond to different pressure rates, leading to hypertension or ... cardiovascular disorders such as heart failure, stroke, coronary artery ... in prevalence each year. WHO estimates that 17 million ...
(Date:5/26/2016)... , May 26, 2016 According ... "Medical Waste Management Market - U.S. Industry Analysis, Size, Share, ... management market in the U.S. was valued at US$ 5.89 ... CAGR of 3.4% from 2015 to 2023 to reach US$ ... analysis of current and emerging needle free drug delivery devices ...
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
Breaking Medicine Technology: